Laura A Solt

List of Publications by Year
in descending order

64 papers	5,296 citations	101543 36 h-index	128289 60 g-index
66 all docs	66 docs citations	66 times ranked	9204 citing authors

#	Article	IF	Citations
1	A Compass to Guide Insights into TH17 Cellular Metabolism and Autoimmunity. Immunometabolism, 2022, 4, .	1.6	0
2	REV-ERBÎ± regulates age-related and oxidative stress-induced degeneration in retinal pigment epithelium via NRF2. Redox Biology, 2022, 51, 102261.	9.0	12
3	Targeting Nuclear Receptors for TH17-Mediated Inflammation: REV-ERBerations of Circadian Rhythm and Metabolism. Immunometabolism, 2022, 4, .	1.6	5
4	High throughput screening for compounds to the orphan nuclear receptor NR2F6. SLAS Discovery, 2022, 27, 242-248.	2.7	3
5	Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity. Immunometabolism, 2021, 3, .	1.6	3
6	Genetic and pharmacological inhibition of the nuclear receptor RORÎ± regulates TH17 driven inflammatory disorders. Nature Communications, 2021, 12, 76.	12.8	27
7	CAR directs T cell adaptation to bile acids in the small intestine. Nature, 2021, 593, 147-151.	27.8	36
8	OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma. Neuro-Oncology Advances, 2021, 3, ii9-ii9.	0.7	0
9	Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBÎ². Science Advances, 2021, 7, .	10.3	13
10	A molecular switch regulating transcriptional repression and activation of PPARÎ³. Nature Communications, 2020, 11, 956.	12.8	45
11	Pharmacological modulation and genetic deletion of REV-ERBÎ± and REV-ERBÎ² regulates dendritic cell development. Biochemical and Biophysical Research Communications, 2020, 527, 1000-1007.	2.1	20
12	Perfect timing: circadian rhythms, sleep, and immunity â€" an NIH workshop summary. JCI Insight, 2020, 5, .	5.0	136
13	Circadian rhythmâ€"dependent and circadian rhythmâ€"independent impacts of the molecular clock on type 3 innate lymphoid cells. Science Immunology, 2019, 4, .	11.9	65
14	The nuclear receptor REV-ERBÎ± modulates Th17 cell-mediated autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18528-18536.	7.1	60
15	PGRMC2 is an intracellular haem chaperone critical for adipocyte function. Nature, 2019, 576, 138-142.	27.8	96
16	Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-Î±. Medicinal Chemistry, 2019, 15, 676-684.	1.5	2
17	REV-ERBÎ² is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Biochemical Pharmacology, 2018, 150, 1-8.	4.4	10
18	REV-ERBÎ± Regulates TH17 Cell Development and Autoimmunity. Cell Reports, 2018, 25, 3733-3749.e8.	6.4	78

#	Article	IF	Citations
19	Distinct roles for REV-ERBÎ± and REV-ERBÎ² in oxidative capacity and mitochondrial biogenesis in skeletal muscle. PLoS ONE, 2018, 13, e0196787.	2.5	18
20	Identification of potent RORÎ² modulators: Scaffold variation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3210-3215.	2.2	3
21	Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-Îº B activation. PLoS Biology, 2018, 16, e2004663.	5.6	29
22	RORÎ± modulates semaphorin 3E transcription and neurovascular interaction in pathological retinal angiogenesis. FASEB Journal, 2017, 31, 4492-4502.	0.5	18
23	Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression. PLoS ONE, 2016, 11, e0151014.	2.5	20
24	Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation. PLoS ONE, 2016, 11, e0162452.	2.5	15
25	Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1. ACS Chemical Biology, 2016, 11, 1795-1799.	3.4	59
26	Metabolism of murine T_H17 cells: Impact on cell fate and function. European Journal of Immunology, 2016, 46, 807-816.	2.9	22
27	Th17 cells in Type 1 diabetes: a future perspective. Diabetes Management, 2015, 5, 247-250.	0.5	13
28	ROR Inverse Agonist Suppresses Insulitis and Prevents Hyperglycemia in a Mouse Model of Type 1 Diabetes. Endocrinology, 2015, 156, 869-881.	2.8	60
29	Suppression of atherosclerosis by synthetic REV-ERB agonist. Biochemical and Biophysical Research Communications, 2015, 460, 566-571.	2.1	73
30	Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell, 2015, 28, 42-56.	16.8	158
31	Nuclear receptor RORÎ± regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10401-10406.	7.1	55
32	Abstract 545: Suppression of Atherosclerosis by Synthetic REV-ERB Agonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
33	Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors. , 2014, , 103-135.		1
34	Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nature Communications, 2014, 5, 5759.	12.8	98
35	Structure of REV-ERBÎ² Ligand-binding Domain Bound to a Porphyrin Antagonist. Journal of Biological Chemistry, 2014, 289, 20054-20066.	3.4	22
36	Noncanonical NF-Îº B Signaling Is Limited by Classical NF-Îº B Activity. Science Signaling, 2014, 7, ra13.	3.6	49

#	Article	IF	Citations
37	Abstract 439: REV-ERB--Mediated Regulation of Cholesterol Biosynthesis and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
38	Rev-erb-Î± modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine, 2013, 19, 1039-1046.	30.7	361
39	A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis. ACS Chemical Biology, 2013, 8, 559-567.	3.4	92
40	Nuclear Receptors and Their Selective Pharmacologic Modulators. Pharmacological Reviews, 2013, 65, 710-778.	16.0	207
41	Identification of SR2211: A Potent Synthetic RORÎ³-Selective Modulator. ACS Chemical Biology, 2012, 7, 672-677.	3.4	126
42	Identification of a Selective RORÎ³ Ligand That Suppresses T_H17 Cells and Stimulates T Regulatory Cells. ACS Chemical Biology, 2012, 7, 1515-1519.	3.4	67
43	Structural and Biophysical Insights into the Ligand-Free Pitx2 Homeodomain and a Ring Dermoid of the Cornea Inducing Homeodomain Mutant. Biochemistry, 2012, 51, 665-676.	2.5	7
44	Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 2012, 485, 62-68.	27.8	638
45	Action of RORs and their ligands in (patho)physiology. Trends in Endocrinology and Metabolism, 2012, 23, 619-627.	7.1	173
46	LXR-Mediated Inhibition of CD4+ T Helper Cells. PLoS ONE, 2012, 7, e46615.	2.5	31
47	Regulation of p53 Stability and Apoptosis by a ROR Agonist. PLoS ONE, 2012, 7, e34921.	2.5	54
48	Identification of SR3335 (ML-176): A Synthetic RORÎ± Selective Inverse Agonist. ACS Chemical Biology, 2011, 6, 218-222.	3.4	114
49	Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature, 2011, 472, 491-494.	27.8	446
50	The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Medicinal Chemistry, 2011, 3, 623-638.	2.3	131
51	Genetic Dissection of the Functions of the Melanocortin-3 Receptor, a Seven-transmembrane G-protein-coupled Receptor, Suggests Roles for Central and Peripheral Receptors in Energy Homeostasis. Journal of Biological Chemistry, 2011, 286, 40771-40781.	3.4	53
52	Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics. Current Opinion in Lipidology, 2010, 21, 204-211.	2.7	55
53	The Benzenesulfoamide T0901317 [<i>N</i>-(2,2,2-Trifluoroethyl)-<i>N</i>-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-Î±/Î³ Inverse Agonist. Molecular Pharmacology, 2010, 77, 228-236.	2.3	221
54	Modulation of Retinoic Acid Receptor-related Orphan Receptor Î± and Î³ Activity by 7-Oxygenated Sterol Ligands. Journal of Biological Chemistry, 2010, 285, 5013-5025.	3.4	180

#	Article	IF	Citations
55	Regulation of FGF21 Expression and Secretion by Retinoic Acid Receptor-related Orphan Receptor Î±. Journal of Biological Chemistry, 2010, 285, 15668-15673.	3.4	98
56	Cutting Edge: Association with IÎºB Kinase Î² Regulates the Subcellular Localization of Homer3. Journal of Immunology, 2010, 185, 2665-2669.	0.8	7
57	Regulation of Adipogenesis by Natural and Synthetic REV-ERB Ligands. Endocrinology, 2010, 151, 3015-3025.	2.8	115
58	NEMO-binding Domains of Both IKKÎ± and IKKÎ² Regulate IÎºB Kinase Complex Assembly and Classical NF-ÎºB Activation. Journal of Biological Chemistry, 2009, 284, 27596-27608.	3.4	40
59	The IÎºB kinase complex: master regulator of NF-ÎºB signaling. Immunologic Research, 2008, 42, 3-18.	2.9	216
60	Hypomorphic nuclear factor-ÎºB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. Journal of Allergy and Clinical Immunology, 2008, 122, 1169-1177.e16.	2.9	240
61	Interleukin-1-induced NF-ÎºB Activation Is NEMO-dependent but Does Not Require IKKÎ². Journal of Biological Chemistry, 2007, 282, 8724-8733.	3.4	75
62	G Protein-Coupled Receptor Ca²⁺-Linked Mitochondrial Reactive Oxygen Species Are Essential for Endothelial/Leukocyte Adherence. Molecular and Cellular Biology, 2007, 27, 7582-7593.	2.3	45
63	The PP2A-Associated Protein Â4 Is an Essential Inhibitor of Apoptosis. Science, 2004, 306, 695-698.	12.6	142
64	Splenic and Peritoneal B-1 Cells Differ in Terms of Transcriptional and Proliferative Features That Separate Peritoneal B-1 from Splenic B-2 Cells. Cellular Immunology, 2001, 213, 62-71.	3.0	36